A group of investors led a $106m financing round in Chinook Therapeutics, a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases. The round includes EcoR1 Capital, OrbiMed, Rock Springs Capital, Avidity Partners, Surveyor Capital, Ally Bridge Group, Monashee Investment Management, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech, Versant Ventures, Apple Tree Partners and Samsara BioCapital. “We’re thrilled to have such a high-quality group of investors support our goal of building a leading kidney disease company to advance multiple clinical programs for IgA nephropathy and other rare, severe chronic kidney diseases with large unmet medical needs. Upon close of our proposed merger with Aduro Biotech, Chinook will be well-capitalized to move its pipeline programs forward towards its objective of providing meaningful results for patients and to prepare pre-commercialization strategies,” Eric Dobmeier, Chinook President and CEO.